Pyrazolopyrimidines in ‘all-natural’ products for erectile dysfunction treatment: the unreliable quality of dietary supplements

References

• Abdel-Jalil RJ, Khanfar M, Abu-Safieh K, Al-Gharabli S, El-Abadelah M, Voelter W. 2005. An efficient one-pot synthesis of pyrazolopyrimidines, intermediates for potential phosphodiesterase inhibitors. Monatsh Chem. 136:619–624.
   Web of Science ®Google Scholar
• Abdel-Jalil RJ, Khanfar M, Al-Gharabli S, El-Abadelah MM, Eichele K, Anwar MU, Voelter W. 2005. High throughput synthesis of pyrazolopyrimidines via copper-catalysed cyclization and x-ray study. Heterocycles. 65:1821–1827.
   Web of Science ®Google Scholar
• Blok-Tip L, Zomer B, Bakker F, Hartog KD, Hamzink M, Ten Hove J, Vredenbregt M, De Kaste D. 2004. Structure elucidation of sildenafil analogues in herbal products. Food Addit Contam. 21:737–748.
   PubMed Web of Science ®Google Scholar
• Chan Lee J, Park C, Choi Y. 1997. A New Procedure for α-Hydroxylation of Ketones Using Thallium(III) p-Nitrobenzenesulfonate (TNS). Synth Commun. 27:4079–4084.
   Web of Science ®Google Scholar
• Crowley R, FitzGerald LH. 2006. The impact of cGMP compliance on consumer confidence in dietary supplement products. Toxicology. 221:9–16.
   PubMed Web of Science ®Google Scholar
• Deisingh AK. 2005. Pharmaceutical counterfeiting. Analyst. 130:271–279.
   PubMed Web of Science ®Google Scholar
• Ellis P, Terrett NK, inventors. 1994. Pyrazolopyrimidinones for the treatment of impotence WO 1994028902 A1.
   Google Scholar
• Ham M. 2003. Health RISKS OF COUNTERFEIT PHARMACEUTICALS. Drug Saf. 26:991–997.
   PubMed Web of Science ®Google Scholar
• Hou P, Zou P, Low M-Y, Chan E, Koh H-L. 2006. Structural identification of a new acetildenafil analogue from pre-mixed bulk powder intended as a dietary supplement. Food Addit Contam. 23:870–875.
   PubMed Web of Science ®Google Scholar
• ICH Q3A (R2) Impurities in New Drug Substances O. 2006.
   Google Scholar
• Instrumental Analysis Data of Illegal Compounds in Food [Internet]. 2010. Korean National Institute for Food and Drug Safety Evaluation. [cited 2013 Nov 13]. Available from: http://nifds.go.kr
   Google Scholar
• Jones AB, editor. 1991. Chapter 2.3: oxidation adjacent to C=X bonds by hydroxylation methods. Oxford: Pergamon Press.
   Google Scholar
• Kagan J, Arora SK, Bryzgis M, Dhawan SN, Reid K, Singh SP, Tow L. 1983. Reaction of phosphorus pentachloride with 2-acetylthiophene and acetophenone. J Org Chem. 48:703–706.
   Web of Science ®Google Scholar
• Khazan M, Hedayati M, Askari S, Azizi F. 2013. Adulteration of products sold as Chinese Herbal medicines for weight loss with thyroid hormones and PCP. J Herbal Med. 3:39–43.
   Google Scholar
• Kim D-K, Lee JY, Lee N, Ryu DH, Kim J-S, Lee S, Choi J-Y, Ryu J-H, Kim N-H, Im G-J, et al. 2001. Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5′-sulfonamide moiety of a phenyl ring. Bioorg Med Chem. 9:3013–3021.
   PubMed Web of Science ®Google Scholar
• Kim J-H, Kim Y, Choi KI, Kim DH, Nam G, Seo JH, inventors. 2002. Preparation of novel pyrazolopyrimidinethiones as phosphodiesterase V inhibitors for treating erectile dysfunction WO2002102802A1.
   Google Scholar
• Kim JY, Hwang IG, Oh JH, Kang IH, Kwon SW, Kim D. 2013. Efficient synthesis of dichlorodenafil, an unapproved sildenafil analogue appearing in non-prescription supplements. Chem Pharm Bull (Tokyo). 61:572–575.
   PubMed Web of Science ®Google Scholar
• Ley SV, Baxendale IR, Brusotti G, Caldarelli M, Massi A, Nesi M. 2002. Solid-supported reagents for multi-step organic synthesis: preparation and application. Il Farmaco. 57:321–330.
   PubMedGoogle Scholar
• Li J-J, Johnson DS, Sliskovic DR, Roth BD, editors. 2004. Chapter 13, PDE 5 inhibitors for erectile dysfunction: sildenafil (Viagra), vardenafil (Levitra), and tadalafil (Cialis). In: Contemporary drug synthesis. Hoboken, NJ: John Wiley & Sons, Inc.; p. 189–199.
   Google Scholar
• Lin M-C, Liu Y-C, Lin Y-L, Lin J-H. 2008. Isolation and identification of a novel sildenafil analogue adulterated in dietary supplements. J Food Drug Anal. 16:15–20.
   Web of Science ®Google Scholar
• Marik PE, Flemmer M. 2012. Do dietary supplements have beneficial health effects in industrialized nations: what is the evidence? J Parenter Enteral Nutr. 36:159–168.
   PubMed Web of Science ®Google Scholar
• Maughan RJ. 2005. Contamination of dietary supplements and positive drug tests in sport. J Sports Sci. 23:883–889.
   PubMed Web of Science ®Google Scholar
• Medrasi HY, Al-Sheikh MA, Salaheldin AM. 2013. Enaminonitriles in heterocyclic synthesis: a route to 1,3-diaryl-4-aminopyrazole derivatives. Molecules. 18:535–544.
   PubMed Web of Science ®Google Scholar
• Patel DN, Li L, Kee C-L., Ge X, Low M-Y., Koh H-L. 2014. Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges. J Pharm Biomed Anal. 87:176–190.
   PubMed Web of Science ®Google Scholar
• Roy J. 2002. Pharmaceutical impurities–a mini-review. AAPS PharmSciTech. 3:1–8.
   PubMedGoogle Scholar
• Slifman NR, Obermeyer WR, Aloi BK, Musser SM, Correll WA, Cichowicz SM, Betz JM, Love LA. 1998. Contamination of botanical dietary supplements by digitalis lanata. N Engl J Med. 339:806–811.
   PubMed Web of Science ®Google Scholar
• Stelzer U, inventor. 1995. Preparation of phenylacetic acids EP665212A1.
   Google Scholar
• Tang MHY, Chen SPL, Ng SW, Chan AYW, Mak TWL. 2011. Case series on a diversity of illicit weight-reducing agents: from the well known to the unexpected. Br J Clin Pharmacol. 71:250–253.
   PubMed Web of Science ®Google Scholar
• Venhuis BJ, De Kaste D. 2012. Towards a decade of detecting new analogues of sildenafil, tadalafil and vardenafil in food supplements: a history, analytical aspects and health risks. J Pharm Biomed Anal. 69:196–208.
   PubMed Web of Science ®Google Scholar
• Venhuis BJ, Zomer G, De Kaste D. 2008. Structure elucidation of a novel synthetic thiono analogue of sildenafil detected in an alleged herbal aphrodisiac. J Pharm Biomed Anal. 46:814–817.
   PubMed Web of Science ®Google Scholar
• Venhuis BJ, Zwaagstra ME, Keizers PH, De Kaste D. 2014. Dose-to-dose variations with single packages of counterfeit medicines and adulterated dietary supplements as a potential source of false negatives and inaccurate health risk assessments. J Pharm Biomed Anal. 89:158–165.
   PubMed Web of Science ®Google Scholar
• Wollein U, Eisenreich W, Schramek N. 2011. Identification of novel sildenafil-analogues in an adulterated herbal food supplement. J Pharm Biomed Anal. 56:705–712.
   PubMed Web of Science ®Google Scholar
• Xia GX, Li JF, Lai SA, Peng AM, Zhang SJ, Wei XH, Chen XJ, Shen JS, Ji RY. 2005. Design and synthesis of pyrido[1,2-e]purin-4(3H)-one derivatives as potential PDE 5 inhibitors. Chin Chem Lett. 16:1283–1286.
   Web of Science ®Google Scholar
• Yu G, Mason H, Wu X, Wang J, Chong S, Beyer B, Henwood A, Pongrac R, Seliger L, He B, et al. 2003. Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction. J Med Chem. 46:457–460.
   PubMed Web of Science ®Google Scholar
• Yuen YP, Lai CK, Poon WT, Ng SW, Chan AY, Mak TW. 2007. Adulteration of over-the-counter slimming products with pharmaceutical analogue–an emerging threat. Hong Kong Med J. 13:216–220.
   PubMedGoogle Scholar